Daclizumab Subcutaneous and Hydrocodone Extended-Release Capsules
Determining the interaction of Daclizumab Subcutaneous and Hydrocodone Extended-Release Capsules and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: daclizumab
Brand name: Zinbryta, Zenapax
Synonyms: Daclizumab
Generic Name: hydrocodone
Brand name: Hysingla ER, Zohydro ER, Vantrela ER
Synonyms: Hydrocodone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daclizumab Subcutaneous-Hydrocodone Extended-Release Tablets
- Daclizumab Subcutaneous-Hydrocodone Polistirex and Chlorpheniramine Polistirex Suspension
- Daclizumab Subcutaneous-Hydrocodone, Chlorpheniramine, and Pseudoephedrine
- Daclizumab Subcutaneous-Hydrocodone, Pseudoephedrine, and Guaifenesin
- Daclizumab Subcutaneous-Hydrocortisone
- Daclizumab Subcutaneous-Hydrocortisone (Systemic)
- Hydrocodone Extended-Release Capsules-Dacogen
- Hydrocodone Extended-Release Capsules-Dacomitinib
- Hydrocodone Extended-Release Capsules-Dactinomycin
- Hydrocodone Extended-Release Capsules-Dactinomycin Injection
- Hydrocodone Extended-Release Capsules-Dactinomycin Intravenous
- Hydrocodone Extended-Release Capsules-Daklinza